CSIMarket Company Name, Ticker, Industry, else..
 
Mereo Biopharma Group Plc  (NASDAQ: MREO)
 
Price: $0.2668 $0.01 5.455%
Day's High: $0.2879999876022339 Week Perf: -5.39 %
Day's Low: $ 0.25 30 Day Perf: -11.66 %
Volume (M): 1,300,271 52 Wk High: $ 2.37
Volume (M$): $ 0 52 Wk Avg: $0.88
Open: $0.25 52 Wk Low: $0.20



 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 160
 Employees 39
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Business Description


Mereo Biopharma Group Plc is a UK-based clinical-stage biopharmaceutical company that focuses on developing innovative therapeutics for rare and specialty diseases. The company is dedicated to developing therapies that have the potential to transform the lives of patients affected by diseases that currently have limited or no treatment options. Mereo Biopharma aims at commercializing these therapies through partnerships or in-house efforts.

Mereo Biopharma has a diversified pipeline of clinical-stage product candidates that range from rare metabolic disorders to oncology. The company's lead program is setrusumab, which is in Phase 3 development for osteogenesis imperfecta, a rare genetic bone disorder. The company also has an active clinical program in the treatment of Alport syndrome, a rare genetic kidney disease. Additionally, the company is developing navicixizumab, which is in Phase 1b/2a development for the treatment of cancers with high unmet medical needs, such as pancreatic and ovarian cancers.

Mereo Biopharma has a strong track record of partnering with leading pharmaceutical companies to advance its pipeline programs to commercialization. The company has formed collaborations with Novartis, Oncomed, and Ultragenyx Pharmaceutical, among others.

Mereo Biopharma was founded in 2015 and is headquartered in London, UK, with offices in the US and Europe. The company has a dedicated team of experienced professionals who have extensive expertise in drug development and commercialization. Mereo Biopharma has a market capitalization of approximately e45 million as of June 202

In summary, Mereo Biopharma is a clinical-stage biopharmaceutical company that aims to address unmet medical needs by developing innovative therapies for rare and specialty diseases. The company has a diversified pipeline of clinical-stage product candidates, a successful partnering strategy, and a talented team of professionals dedicated to transforming the lives of patients through cutting-edge therapeutics.


   Company Address: One Cavendish Place London 0
   Company Phone Number: 333-023-7300   Stock Exchange / Ticker: NASDAQ MREO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
PFE        1.75% 
• View Complete Report
   



Financing Agreement

Mereo BioPharma Raises $50 Million in Underwritten Offering, Focusing on Rare Diseases

Published Fri, Jun 14 2024 11:51 AM UTC



London-based clinical-stage biopharmaceutical company, Mereo BioPharma Group plc, has recently disclosed the pricing of its underwritten offering of 12,531,300 American Depositary Shares (ADSs). Priced at $3.99 per ADS, the offering is expected to generate approximately $50.0 million in gross proceeds. Mereo plans to utilize these funds primarily for the advancemen...
Product Service News

Mereo BioPharma Sets Pace for 2024: Eyes Completion of Key Clinical Trials and Exciting Pipeline Developments.

Published Mon, Jan 8 2024 12:02 PM UTC

Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the potential to transform the life of patients globally. The compan...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 85.57
Price to Sales (Expected) -
Price to Book 0.95
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.71
Working Capital Ratio 8.02
Leverage Ratio (MRQ) 0.19
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.22 $
Revenues (TTM) 0 $
Cash Flow (TTM) -
Cash 0.3 $
Book Value 0.28 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -915,641
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.